218 related articles for article (PubMed ID: 18587385)
21. Effect of angiogenesis inhibitor TNP-470 on the growth, blood flow, and microvessel density in xenografts of human uterine carcinosarcoma in nude mice.
Emoto M; Ishiguro M; Iwasaki H; Kikuchi M; Kawarabayashi T
Gynecol Oncol; 2003 Apr; 89(1):88-94. PubMed ID: 12694659
[TBL] [Abstract][Full Text] [Related]
22. Effects of angiogenesis inhibitor TNP-470 on tamoxifen-stimulated MCF-7 breast tumors in nude mice.
Takei H; Lee ES; Cisneros A; Jordan VC
Cancer Lett; 2000 Jul; 155(2):129-35. PubMed ID: 10822127
[TBL] [Abstract][Full Text] [Related]
23. [Effects of HCFU and TNP 470 on liver metastasis of BALB/c retroperitoneal sarcoma (LMFS)].
Fujii Y; Iwasa H; Hirai J; Hasumi K; Eriguchi M
Gan To Kagaku Ryoho; 1999 Nov; 26(13):2061-7. PubMed ID: 10584572
[TBL] [Abstract][Full Text] [Related]
24. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma.
Teicher BA; Holden SA; Dupuis NP; Kakeji Y; Ikebe M; Emi Y; Goff D
Breast Cancer Res Treat; 1995; 36(2):227-36. PubMed ID: 8534870
[TBL] [Abstract][Full Text] [Related]
25. Antiangiogenic and antitumor effects of tranilast on mouse lung carcinoma cells.
Yatsunami J; Aoki S; Fukuno Y; Kikuchi Y; Kawashima M; Hayashi SI
Int J Oncol; 2000 Dec; 17(6):1151-6. PubMed ID: 11078800
[TBL] [Abstract][Full Text] [Related]
26. Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder.
Inoue K; Chikazawa M; Fukata S; Yoshikawa C; Shuin T
Clin Cancer Res; 2002 Jul; 8(7):2389-98. PubMed ID: 12114444
[TBL] [Abstract][Full Text] [Related]
27. Specific cell targeting with APRPG conjugated PEG-PLGA nanoparticles for treating ovarian cancer.
Wang Y; Liu P; Duan Y; Yin X; Wang Q; Liu X; Wang X; Zhou J; Wang W; Qiu L; Di W
Biomaterials; 2014 Jan; 35(3):983-92. PubMed ID: 24176193
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cisplatin.
Shishido T; Yasoshima T; Denno R; Mukaiya M; Sato N; Hirata K
Jpn J Cancer Res; 1998 Sep; 89(9):963-9. PubMed ID: 9818033
[TBL] [Abstract][Full Text] [Related]
29. Antitumor activity of the angiogenesis inhibitor TNP-470 on murine lymphoma/leukemia cells in vivo and in vitro.
Norén-Nyström U; Eriksson M; Eriksson B; Roos G; Bergh A; Holmberg D
Exp Hematol; 2003 Feb; 31(2):143-9. PubMed ID: 12591279
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of expression of vascular endothelial growth factor and its receptors in pulmonary adenocarcinoma cell by TNP-470 in combination with gemcitabine.
Wang XF; Tu LF; Wang LH; Zhou JY
J Zhejiang Univ Sci B; 2006 Oct; 7(10):837-43. PubMed ID: 16972327
[TBL] [Abstract][Full Text] [Related]
31. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma.
Murata R; Nishimura Y; Hiraoka M
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1107-13. PubMed ID: 9169820
[TBL] [Abstract][Full Text] [Related]
32. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470.
Satchi-Fainaro R; Puder M; Davies JW; Tran HT; Sampson DA; Greene AK; Corfas G; Folkman J
Nat Med; 2004 Mar; 10(3):255-61. PubMed ID: 14981512
[TBL] [Abstract][Full Text] [Related]
33. Effect of angiogenesis inhibitor TNP-470 on vascular formation in pituitary tumors induced by estrogen in rats.
Takechi A
Neurol Med Chir (Tokyo); 1994 Nov; 34(11):729-33. PubMed ID: 7533265
[TBL] [Abstract][Full Text] [Related]
34. Antitumor effect of arterial administration of a medium-chain triglyceride solution of an angiogenesis inhibitor, TNP-470, in rabbits bearing VX-2 carcinoma.
Yanai S; Okada H; Saito K; Kuge Y; Misaki M; Ogawa Y; Toguchi H
Pharm Res; 1995 May; 12(5):653-7. PubMed ID: 7479548
[TBL] [Abstract][Full Text] [Related]
35. Antitumor effect of TNP-470, an angiogenesis inhibitor, combined with ultrasound irradiation for human uterine sarcoma xenografts evaluated using contrast color Doppler ultrasound.
Emoto M; Tachibana K; Iwasaki H; Kawarabayashi T
Cancer Sci; 2007 Jun; 98(6):929-35. PubMed ID: 17433035
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470.
Yazaki T; Takamiya Y; Costello PC; Mineta T; Menon AG; Rabkin SD; Martuza RL
J Neurooncol; 1995; 23(1):23-9. PubMed ID: 7542695
[TBL] [Abstract][Full Text] [Related]
37. Inhibitory effects of the antiangiogenic agent TNP-470 on establishment and growth of hematogenous metastasis of human pancreatic carcinoma in SCID beige mice in vivo.
Kawarada Y; Ishikura H; Kishimoto T; Saito K; Takahashi T; Kato H; Yoshiki T
Pancreas; 1997 Oct; 15(3):251-7. PubMed ID: 9336788
[TBL] [Abstract][Full Text] [Related]
38. TNP-470/minocycline/cytotoxic therapy: a systems approach to cancer therapy.
Teicher BA; Emi Y; Kakeji Y; Northey D
Eur J Cancer; 1996 Dec; 32A(14):2461-6. PubMed ID: 9059334
[No Abstract] [Full Text] [Related]
39. Treatment of metastatic liver tumors by intermittent repetitive injection of an angiogenesis inhibitor using an implantable port system in a rabbit model.
Kuwata Y; Hirota S; Sako M
Kobe J Med Sci; 1997 Apr; 43(2):83-98. PubMed ID: 9385787
[TBL] [Abstract][Full Text] [Related]
40. Optimizing the dosing schedule of TNP-470 [O-(chloroacetyl-carbamoyl) fumagillol] enhances its antitumor and antiangiogenic efficacies.
Koyanagi S; Nakagawa H; Kuramoto Y; Ohdo S; Soeda S; Shimeno H
J Pharmacol Exp Ther; 2003 Feb; 304(2):669-74. PubMed ID: 12538820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
